BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Onglyza (Saxagliptin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Onglyza (Saxagliptin)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02969798-298@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Onglyza (Saxagliptin): Phase na readout est. (NCT02969798)
DESCRIPTION:Onglyza (Saxagliptin)\, phase na\, Type 2 Diabetes.\nStudy: Pre
 -diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Gluc
 ose Tolerance (IGT)\nEstimated primary completion: 28 February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/saxagliptin#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT02969798
URL:https://assetmemo.bio/drug/saxagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918274-298@assetmemo.bio
DTSTAMP:20261121T005635Z
DTSTART;VALUE=DATE:20291030
DTEND;VALUE=DATE:20291031
SUMMARY:Onglyza (Saxagliptin): Phase 2 readout est. (NCT07918274)
DESCRIPTION:Onglyza (Saxagliptin)\, phase 2.\nStudy: Restoring Awareness\nE
 stimated primary completion: 30 October 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/saxagliptin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07918274
URL:https://assetmemo.bio/drug/saxagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
